Michael Carrier(@profmikecarrier) 's Twitter Profileg
Michael Carrier

@profmikecarrier

Professor at Rutgers Law School specializing in antitrust and IP law. @[email protected]

ID:1275989323

linkhttp://camlaw.rutgers.edu/directory/mcarrier/ calendar_today17-03-2013 20:53:51

5,9K Tweets

2,2K Followers

1,2K Following

Marc Edelman(@MarcEdelman) 's Twitter Profile Photo

I believe this is exactly what Michael Carrier and I had suggested as one of the less restrictive alternatives to the transfer rules in our 2019 Michigan Law Review article. It's nice, in some small way, to make a difference.

papers.ssrn.com/sol3/papers.cf…

account_circle
Michael Carrier(@profmikecarrier) 's Twitter Profile Photo

Pleased to see that DOJ is planning to sue Ticketmaster-Live Nation. Here’s my 4-minute overview of why the company violates antitrust law and should be broken up.
omny.fm/shows/wcbsam-o…

account_circle
Michael Carrier(@profmikecarrier) 's Twitter Profile Photo

Thanks to the 69 professors who signed onto my brief in the Maryland district court explaining why a brand drug firm’s refusal to share a sample a generic needs to enter the market could violate antitrust law. papers.ssrn.com/sol3/papers.cf…

account_circle
Rutgers Institute for Info. Policy and Law (RIIPL)(@RIIPL_RLAW) 's Twitter Profile Photo

On 4/16, Tom Holsten, Vice President and Chief IP Counsel at International Flavors & Fragrances, will discuss differences between law firm and in house IP practice and advice regarding starting off in IP.

Register: go.rutgers.edu/iplunch

On 4/16, Tom Holsten, Vice President and Chief IP Counsel at International Flavors & Fragrances, will discuss differences between law firm and in house IP practice and advice regarding starting off in IP. Register: go.rutgers.edu/iplunch
account_circle
Michael Carrier(@profmikecarrier) 's Twitter Profile Photo

Some say pharma patent thickets not concerning b/c high tech thickets even bigger. Relying on industry characteristics & empirical evidence on continuation patents, S. Sean Tu & I explain argument wrong and pharma thickets designed to be anticompetitive. papers.ssrn.com/sol3/papers.cf…

account_circle
Marc Edelman(@MarcEdelman) 's Twitter Profile Photo

This makes sense to me. It kind of goes along with what Michael Carrier and I have been suggesting for years to avoid liability:

2024 article (forthcoming): papers.ssrn.com/sol3/papers.cf…

2019 article:
papers.ssrn.com/sol3/papers.cf…

account_circle
Marc Edelman(@MarcEdelman) 's Twitter Profile Photo

My 2013 antitrust treatise on amateurism and antitrust law remains on point:
papers.ssrn.com/sol3/papers.cf…

As does this piece by Michael Carrier and me on transfer rules:
papers.ssrn.com/sol3/papers.cf…

account_circle
Michael Carrier(@profmikecarrier) 's Twitter Profile Photo

Pleased to see this. Marc Edelman & I have raised antitrust concerns with the 45-day transfer window: papers.ssrn.com/sol3/papers.cf…

account_circle
Michael Carrier(@profmikecarrier) 's Twitter Profile Photo

Time’s Person of Year Taylor Swift very impressive but not have own ticketing company. 2022 tour reminded us of Ticketmaster ticketing disaster. I explain why Live Nation Entertainment is a walking antitrust violation and needs to be broken up. papers.ssrn.com/sol3/papers.cf…

account_circle
Marc Edelman(@MarcEdelman) 's Twitter Profile Photo

Do you think the newest restraints on college athlete transfers are legal? @Profmikecarrier and I explain why possibly not under law, in a draft of a forthcoming article in Texas A&M Law Review. papers.ssrn.com/sol3/papers.cf…

account_circle
Christopher Yasiejko 🌻🇺🇦(@yasiejko) 's Twitter Profile Photo

“These challenges could deter drug companies from listing similar patents in the Orange Book in the future. One challenge, though, is that sometimes the FDA is unclear on whether a patent should be listed.”
—@ProfMikeCarrier, antitrust, Rutgers Law ⚖️

account_circle
Michael Carrier(@profmikecarrier) 's Twitter Profile Photo

We sometimes hear that innovation is reflected solely by the initial invention. And that any weakening of patents or application of antitrust will harm innovation. I explain how these arguments do not capture the multi-generational nature of innovation.
papers.ssrn.com/sol3/papers.cf…

account_circle